BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30248670)

  • 1. Effect of Ascorbic Acid on Mineral and Bone Disorders in Hemodialysis Patients: a Systematic Review and Meta-Analysis.
    Ke G; Huang J; Zhu Y; Yang J; Zhang Y; Chen L; Hu J; Tao S; Hu Y; Yang D; Liu S
    Kidney Blood Press Res; 2018; 43(5):1459-1471. PubMed ID: 30248670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).
    Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL;
    Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Magnesium Supplementation on Chronic Kidney Disease-Mineral and Bone Disorder in Hemodialysis Patients: A Meta-Analysis of Randomized Controlled Trials.
    Guo G; Zhou J; Xu T; Sheng Z; Huang A; Sun L; Yao L
    J Ren Nutr; 2022 Jan; 32(1):102-111. PubMed ID: 34531112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of randomized controlled trials of tonifying kidney and strengthen bone therapy on nondialysis patients with chronic kidney disease-mineral and bone disorder.
    Wu G; Li L; Wu Z
    Medicine (Baltimore); 2023 Jun; 102(25):e34044. PubMed ID: 37352066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D compounds for people with chronic kidney disease requiring dialysis.
    Palmer SC; McGregor DO; Craig JC; Elder G; Macaskill P; Strippoli GF
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005633. PubMed ID: 19821349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
    Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
    Cozzolino M; Messa P; Brancaccio D; Cannella G; Bolasco P; Di Luca M; Costanzo AM; Paparatti Ud; Festa V; Gualberti G; Mazzaferro S;
    Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
    Gasu V; Ashong M; Seferi A; Fitzpatrick A
    JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differences in acid-base status and the calcium parathyroid axis between peritoneal dialysis and hemodialysis.
    Morishita M; Matsuo N; Maruyama Y; Nakao M; Yamamoto I; Tanno Y; Ohkido I; Ikeda M; Yokoyama K; Yokoo T
    Clin Nephrol; 2016 Aug; 86(2):55-61. PubMed ID: 27345183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients.
    Streja E; Wang HY; Lau WL; Molnar MZ; Kovesdy CP; Kalantar-Zadeh K; Park J
    Bone; 2014 Apr; 61():201-7. PubMed ID: 24486956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D receptor gene polymorphism detected by digestion with Apa I influences the parathyroid response to extracellular calcium in Japanese chronic dialysis patients.
    Yokoyama K; Shigematsu T; Kagami S; Tsukada T; Arai T; Hara S; Yamada A; Kawaguchi Y; Hosoya T
    Nephron; 2001 Nov; 89(3):315-20. PubMed ID: 11598396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W; Chaiyakum A; Pongskul C
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for bone disease in children with chronic kidney disease.
    Geary DF; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2010 Jan; (1):CD008327. PubMed ID: 20091666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
    Palmer SC; Hayen A; Macaskill P; Pellegrini F; Craig JC; Elder GJ; Strippoli GF
    JAMA; 2011 Mar; 305(11):1119-27. PubMed ID: 21406649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.